Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

The U.S. Food and Drug Administration has its hands full making sure medical AI products are safe, efficacious and trustworthy before they hit the market. The rise of ever-more-innovative iterations of the technology—not least generative AI—is only adding to the burden. 

Among AI’s most watchful stakeholders are healthcare organizations in need of AI talent and AI talent in need of work in healthcare. Both groups need to keep up with the technology in its present as well as future iterations.

Some 60% of IT professionals and 51% of operational leaders admit they’re reluctant to involve clinicians in software decisions. 

The hospital was prepared for Hurricane Helene and has maintained operations, despite being in the epicenter of destruction.

Patient outcomes, safety data and physician feedback were all used to rank the top children's hospitals for pediatric cardiology and heart surgery in the United States. Did your facility make the cut? 

As 2024 winds down and the number of FDA-approved medical devices packing AI approaches 1,000—the agency had the tally at 950 as of August—the industry finds itself at a “critical inflection point.” 

Nurses tend to feel optimistic if not exactly excited about AI’s advances into their profession. Those who hold back tend to share a common concern—sacrificing care quality for the sake of tech-enabled efficiency.